Actos Tablets specified drug-use survey <Survey on glycemic control in type 2 diabetic patients with a history of cerebral infarction>

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-jRCT1080222517
• Lead Sponsor: TAKEDA PHARMACEUTICAL COMPANY LTD.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-06-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Type 2 diabetic patients with a prior history of cerebral infarction who meet all the following conditions, [1] to [3], at the time of enrollment in the survey:
[1] First onset of cerebral infarction was at least 24 weeks prior to enrollment
[2] HbA1c values >= 6.5% within 12 weeks prior to the start of treatment with Actos Tablets
[3] No prior history of treatment with Actos Tablets since the first onset of cerebral infarction

Exclusion Criteria

Patients who meet any of the following conditions, [1] to [5], shall be excluded from the survey:
[1] Contraindication for Actos Tablets
[2] Prior history of recurrence of cerebral infarction
[3] Prior history of cerebral hemorrhage or subarachnoid hemorrhage
[4] Complications or prior history of myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease, atrial fibrillation, atrial flutter, or valvular disease
[5] Reduced cardiac function (defined as an ejection fraction [EF] <= 40%)

Study & Design

• Study Type: Observational
• Study Design: Not specified